Assessment of tumor biomarkers based on a Turkish city hospital’s data
Medicine Science, cilt.14, sa.3, ss.864-869, 2025 (TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 14 Sayı: 3
- Basım Tarihi: 2025
- Doi Numarası: 10.5455/medscience.2025.02.058
- Dergi Adı: Medicine Science
- Derginin Tarandığı İndeksler: TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.864-869
- Ankara Yıldırım Beyazıt Üniversitesi Adresli: Evet
Özet
Biomarkers can be objectively measured and evaluate the processes of normal biological pathogenic, and pharmacological answers to medications. This study aimed to evaluate the Cancer antigen 15-3 (CA 15-3); Cancer antigen 19-9 (CA 19-9); Cancer antigen 72-4 (CA 72-4); Cancer antigen 125 (CA 125); Carcinoembryonic antigen (CEA); Neuron-specific enolase (NSE), and their test requests in Ankara Bilkent City Hospital. All the results recorded between 01/01/2022 and 31/12/2022 were acquired from our hospital laboratory information system.136,043 tests, consisting of 28,132 CA 15-3, 37,543 CA 19-9, 3135 CA 72-4, 29,996 CA125, 36,788 CEA, and 449 NSE tests, were enrolled. The frequency of positive tumor markers were as follows: CA 15-3 U/mL (N=996, 3.5%), CA 19-9 U/mL (N=4716,12.6%), CA 72-4 U/ mL (N=174, 5.6 %), CA125 U/mL (N=3488, 11.6%), CEA ng/mL (N=1699, 4.6%), NSE IU/ mL (N=396, 88.2%). Statistical differences in CA 15-3 U/mL(p<0.001), CA 19-9 U/mL (p=0.016), CA125 U/mL(p<0.001), CEA ng/mLp<0.001), and NSE IU/ Ml (p<.001) tests among genders, and statistical differences in CA 15-3(p<0.001), CA19-9 (p<0.001), CA 72-4 (p=0.038), CA125(p<0.001), CEA(p<0.001), NSE(p<0.01) among age intervals were observed. Our findings may indicate that; tumor biomarker tests may be requested with a low specific diagnosis purpose. Inappropriate testing orders for tumor biomarkers may increase the risk of false above-reference results. patient may experience fear and anxiety, hospital costs may increase. Clinicians should consider all these circumstances before requesting tumor biomarker tests.